Search Tag: liver cancer
2025 09 Nov
Hepatocellular carcinoma (HCC) continues to drive significant morbidity and mortality. Microvascular invasion (MVI) is a key marker of aggressive biology, yet confirmation usually arrives only after surgery. An MRI-based approach now captures how uneven the tumour and its immediate surroundings appear on routine sequences, turning those patterns...Read more
2025 31 Oct
Primary liver cancer is a major cause of cancer-related death and hepatocellular carcinoma (HCC) accounts for most cases. Surveillance aims to find disease earlier in people at risk, yet ultrasound, the main tool for routine monitoring, can miss small or subtle lesions. More intensive imaging can detect disease earlier but is demanding for services...Read more
2025 31 Oct
Primary liver cancer is a major cause of cancer-related death and hepatocellular carcinoma (HCC) accounts for most cases. Surveillance aims to find disease earlier in people at risk, yet ultrasound, the main tool for routine monitoring, can miss small or subtle lesions. More intensive imaging can detect disease earlier but is demanding for services...Read more
2025 31 Oct
Primary liver cancer is a major cause of cancer-related death and hepatocellular carcinoma (HCC) accounts for most cases. Surveillance aims to find disease earlier in people at risk, yet ultrasound, the main tool for routine monitoring, can miss small or subtle lesions. More intensive imaging can detect disease earlier but is demanding for services...Read more
2025 29 Sep
Knowing how aggressive a liver tumour is before treatment can shape decisions on surgery and follow-up. Pathology remains the benchmark for confirming tumour behaviour, yet it becomes available only after resection. Contrast-enhanced ultrasound (CEUS) provides a real-time view of blood flow in and around hepatocellular carcinoma, but visual interpretation...Read more
2025 29 Sep
Knowing how aggressive a liver tumour is before treatment can shape decisions on surgery and follow-up. Pathology remains the benchmark for confirming tumour behaviour, yet it becomes available only after resection. Contrast-enhanced ultrasound (CEUS) provides a real-time view of blood flow in and around hepatocellular carcinoma, but visual interpretation...Read more
2025 09 Sep
Accurate preoperative distinction between hepatocellular carcinoma, intrahepatic cholangiocarcinoma and hepatic inflammatory pseudotumour remains difficult on routine imaging and serum markers, yet the consequences are significant. HCC and ICC often require surgery or systemic therapy, whereas HIPT is benign and may be managed conservatively,...Read more
2025 02 Sep
Microvascular invasion is a key histopathological feature linked to recurrence and poor survival in hepatocellular carcinoma, yet it is confirmed only after surgery, limiting its value for preoperative decision-making. A retrospective multicentre analysis of 655 surgically confirmed cases explored whether three-dimensional fractal dimension derived...Read more
2025 02 Sep
Microvascular invasion is a key histopathological feature linked to recurrence and poor survival in hepatocellular carcinoma, yet it is confirmed only after surgery, limiting its value for preoperative decision-making. A retrospective multicentre analysis of 655 surgically confirmed cases explored whether three-dimensional fractal dimension derived...Read more
2025 25 Aug
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with significant challenges in diagnosis, risk stratification and treatment selection. While imaging has long been a cornerstone of HCC diagnosis, emerging evidence supports its role in identifying prognostic and predictive markers. These markers offer...Read more
2025 25 Aug
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with significant challenges in diagnosis, risk stratification and treatment selection. While imaging has long been a cornerstone of HCC diagnosis, emerging evidence supports its role in identifying prognostic and predictive markers. These markers offer...Read more
2025 06 Jul
Hepatocellular carcinoma (HCC) is a major global health burden and ranks among the leading causes of cancer-related deaths. Despite curative treatments such as liver resection or transplantation, HCC exhibits high recurrence rates, often due to microvascular invasion (MVI), a pathological hallmark of tumour aggressiveness. Accurate preoperative...Read more
2025 01 Jul
Accurate identification of contrast phases in abdominal CT imaging is critical for detecting liver diseases and optimising diagnostic quality. Each phase—early arterial (EAP), late arterial (LAP), portal venous (PVP) and delayed (DP)—offers unique visual information essential for identifying lesions, particularly hepatocellular carcinoma. However,...Read more
2025 01 Jul
Accurate identification of contrast phases in abdominal CT imaging is critical for detecting liver diseases and optimising diagnostic quality. Each phase—early arterial (EAP), late arterial (LAP), portal venous (PVP) and delayed (DP)—offers unique visual information essential for identifying lesions, particularly hepatocellular carcinoma. However,...Read more
2025 04 May
Hepatocellular carcinoma (HCC) remains a major global health challenge, being the third leading cause of cancer-related mortality. Its aggressive variants, particularly the proliferative subtype, are associated with poor prognoses and high recurrence rates post-surgery. Traditional diagnostic approaches rely heavily on invasive methods like histopathology,...Read more
2025 04 May
Hepatocellular carcinoma (HCC) remains a major global health challenge, being the third leading cause of cancer-related mortality. Its aggressive variants, particularly the proliferative subtype, are associated with poor prognoses and high recurrence rates post-surgery. Traditional diagnostic approaches rely heavily on invasive methods like histopathology,...Read more
2025 09 Feb
Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadly malignancies worldwide. Among patients with small late-recurrent HCC, choosing an optimal treatment strategy is critical to improving survival and maintaining quality of life. Traditionally, surgical resection (SR) has been the primary curative approach, but less invasive...Read more
2025 29 Jan
Hepatocellular carcinoma (HCC) is a major global health challenge, ranking as the sixth most common cancer and the fourth leading cause of cancer-related death worldwide. Early detection and precise monitoring are crucial for improving patient outcomes, especially in high-risk individuals with liver cirrhosis or chronic hepatitis infections....Read more
2025 14 Jan
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a significant cause of cancer-related mortality globally. Early-stage HCC offers better treatment prospects compared to advanced cases, yet predicting tumour growth rates remains a major clinical challenge. Tumour volume doubling time (TVDT) can vary significantly among individual...Read more
2024 10 Nov
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, poses unique diagnostic and therapeutic challenges due to its complex biological behaviour. Intratumoural fat—fat deposits within the tumour tissue—has become an area of focus as it appears to be associated with different prognostic outcomes. MRI imaging has proven essential...Read more